Tri Locum Partners
Latest statistics and disclosures from Tri Locum Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are JNJ, UTHR, MRK, AXSM, ASND, and represent 49.45% of Tri Locum Partners's stock portfolio.
- Added to shares of these 10 stocks: JNJ (+$56M), UTHR (+$51M), MRK (+$38M), VERA (+$23M), AXSM (+$16M), XENE (+$15M), SLNO (+$11M), KRRO (+$9.5M), STVN (+$8.6M), ABBV (+$7.9M).
- Started 6 new stock positions in JNJ, STVN, XENE, DNTH, UTHR, MRK.
- Reduced shares in these 10 stocks: TEVA (-$34M), , VRNA (-$21M), INSP (-$19M), , MDGL (-$14M), EOLS (-$11M), , PRAX (-$6.3M), LEGN (-$6.1M).
- Sold out of its positions in ALNY, EOLS, FEMY, INSP, ISRG, LEGN, NUVL, WGS, TEVA, UNH. VRNA.
- Tri Locum Partners was a net buyer of stock by $59M.
- Tri Locum Partners has $435M in assets under management (AUM), dropping by 32.03%.
- Central Index Key (CIK): 0001826434
Tip: Access up to 7 years of quarterly data
Positions held by Tri Locum Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Tri Locum Partners
Tri Locum Partners holds 18 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | 12.9 | $56M | NEW | 303k | 185.42 |
|
| United Therapeutics Corporation (UTHR) | 11.8 | $51M | NEW | 122k | 419.21 |
|
| Merck & Co (MRK) | 8.6 | $38M | NEW | 447k | 83.93 |
|
| Axsome Therapeutics (AXSM) | 8.2 | $36M | +85% | 292k | 121.45 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 8.0 | $35M | +18% | 175k | 198.81 |
|
| Vera Therapeutics Cl A (VERA) | 8.0 | $35M | +188% | 1.2M | 29.06 |
|
| Argenx Se Sponsored Adr (ARGX) | 7.4 | $32M | -9% | 43k | 737.56 |
|
| Madrigal Pharmaceuticals (MDGL) | 7.1 | $31M | -30% | 68k | 458.66 |
|
| Soleno Therapeutics (SLNO) | 7.0 | $31M | +55% | 451k | 67.60 |
|
| Abbvie (ABBV) | 4.8 | $21M | +61% | 90k | 231.54 |
|
| Korro Bio (KRRO) | 3.7 | $16M | +142% | 338k | 47.89 |
|
| Xenon Pharmaceuticals (XENE) | 3.4 | $15M | NEW | 366k | 40.15 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 2.5 | $11M | -28% | 725k | 15.27 |
|
| Stevanato Group S P A Ord Shs (STVN) | 2.0 | $8.6M | NEW | 333k | 25.75 |
|
| Dianthus Therapeutics (DNTH) | 1.7 | $7.2M | NEW | 183k | 39.35 |
|
| Tarsus Pharmaceuticals (TARS) | 1.6 | $7.1M | -32% | 119k | 59.43 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.9 | $4.0M | -61% | 76k | 53.00 |
|
| Biohaven (BHVN) | 0.5 | $2.2M | -45% | 149k | 15.01 |
|
Past Filings by Tri Locum Partners
SEC 13F filings are viewable for Tri Locum Partners going back to 2020
- Tri Locum Partners 2025 Q3 filed Nov. 14, 2025
- Tri Locum Partners 2025 Q2 filed Aug. 14, 2025
- Tri Locum Partners 2025 Q1 filed May 14, 2025
- Tri Locum Partners 2024 Q4 filed Feb. 14, 2025
- Tri Locum Partners 2024 Q3 filed Nov. 14, 2024
- Tri Locum Partners 2024 Q2 filed Aug. 14, 2024
- Tri Locum Partners 2024 Q1 filed May 15, 2024
- Tri Locum Partners 2023 Q4 filed Feb. 14, 2024
- Tri Locum Partners 2023 Q3 filed Nov. 14, 2023
- Tri Locum Partners 2023 Q2 filed Aug. 14, 2023
- Tri Locum Partners 2023 Q1 filed May 15, 2023
- Tri Locum Partners 2022 Q4 filed Feb. 14, 2023
- Tri Locum Partners 2022 Q3 filed Nov. 14, 2022
- Tri Locum Partners 2022 Q2 filed Aug. 15, 2022
- Tri Locum Partners 2022 Q1 filed May 16, 2022
- Tri Locum Partners 2021 Q4 filed Feb. 14, 2022